Table 2.
Temporal changes in clinical parameters and CKD-MBD medication use in overall patients (N = 596)
| Parameter | Baseline | Follow-up | p value | |||
|---|---|---|---|---|---|---|
| –1Q; ref | Q1 | Q2 | Q3 | Q4 | ||
| CKD-MBD biochemical markers | ||||||
| sP, mg/dL | 5.78 (0.05) | 5.52 (0.05)*** | 5.49 (0.05)*** | 5.42 (0.05)*** | 5.50 (0.05)*** | <0.0001 |
| sP ≤5.5, mg/dL | 43.3 | 55.2*** | 57.5*** | 60.2*** | 58.0*** | <0.0001 |
| sP ≤4.5, mg/dL | 5.9 | 20.6*** | 21.0*** | 24.2*** | 22.7*** | <0.0001 |
| Serum calcium, mg/dL | 8.90 (0.02) | 8.97 (0.02)*** | 8.96 (0.02)*** | 8.96 (0.02)*** | 8.92 (0.02) | <0.0001 |
| iPTH, pg/mL | 535 (15) | 482 (15)*** | 475 (15)*** | 461 (15)*** | 469 (15)*** | <0.0001 |
| CKD-MBD medications | ||||||
| PB pills/day | 0 | 3.7 (0.06) | 3.9 (0.06) | 4.1 (0.06) | 4.2 (0.06) | NA |
| Cinacalcet use | 8.2 | 14.8*** | 17.1*** | 18.6*** | 21.3*** | <0.0001 |
| Home cinacalcet dose, mg/day | 27.5 (3.4) | 38.4 (2.9)** | 42.4 (2.7)*** | 43.3 (2.7)*** | 46.7 (2.6)*** | <0.0001 |
| In-center cinacalcet dose, mg/administration | 21.8 (4.0) | 34.3 (3.4)*** | 43.1 (3.3)*** | 57.1 (3.3)*** | 65.6 (3.2)*** | <0.0001 |
| Etelcalcetide use | 0.5 | 1.2* | 3.0** | 4.0*** | 5.4*** | <0.0001 |
| Etelcalcetide dose, μg/administration | 4.03 (0.92) | 4.19 (0.69) | 4.94 (0.55) | 5.76 (0.51)* | 6.18 (0.48)* | 0.003 |
| Any vitamin D use | 61.2 | 70.1*** | 74.3*** | 77.7*** | 82.4*** | <0.0001 |
| Oral active vitamin D usea | 49.5 | 56.4*** | 58.6*** | 60.1*** | 63.8*** | <0.0001 |
| IV active vitamin D useb | 13.8 | 15.8* | 17.6** | 19.1*** | 20.5*** | <0.0001 |
| Nutritional and clearance parameters | ||||||
| Serum albumin, g/dL | 3.68 (0.01) | 3.79 (0.01)*** | 3.84 (0.01)*** | 3.86 (0.01)*** | 3.85 (0.01)*** | <0.0001 |
| Predialysis weight, kg | 89.3 (1.0) | 89.8 (1.0)*** | 90.5 (1.0)*** | 90.9 (1.0)*** | 91.2 (1.0)*** | <0.0001 |
| enPCR, g/kg/day | 0.86 (0.01) | 0.91 (0.01)*** | 0.92 (0.01)*** | 0.91 (0.01)*** | 0.91 (0.01)*** | <0.0001 |
| eKt/V | 1.43 (0.01) | 1.44 (0.01) | 1.46 (0.01)* | 1.46 (0.01)* | 1.46 (0.01)* | 0.05 |
Values are presented as least-squares mean (standard error) or %. p values compare the summary estimates across time with -Q1 as the reference. Overall p values were calculated using linear mixed-effects regression (continuous variables) or Cochran’s Q test (categorical variables). CKD-MBD, chronic kidney disease-mineral and bone disorder; eKt/V, equilibrated Kt/V; enPCR, equilibrated normalized protein catabolic rate; iPTH, intact parathyroid hormone; IV, intravenous; NA, not applicable; PB, phosphate binder; sP, serum phosphorus.
*p < 0.05; **p < 0.001; ***p < 0.0001 (vs. baseline).
aIncludes calcitriol and doxercalciferol.
bIncludes doxercalciferol, calcitriol, and paricalcitol.